POTS
MCID: PST048
MIFTS: 46

Postural Orthostatic Tachycardia Syndrome (POTS)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Postural Orthostatic Tachycardia Syndrome

MalaCards integrated aliases for Postural Orthostatic Tachycardia Syndrome:

Name: Postural Orthostatic Tachycardia Syndrome 12 53 54 44 15 73
Familial Orthostatic Tachycardia Due to Norepinephrine Transporter Deficiency 12 53
Postural Tachycardia Syndrome Due to Net Deficiency 12 53
Orthostatic Intolerance Due to Net Deficiency 12 53
Mitral Valve Prolapse Syndrome 12 73
Postural Tachycardia Syndrome 53 54
Neurocirculatory Asthenia 12 73
Irritable Heart 12 73
Postural Orthostatic Tachycardia Syndrome Due to Net Deficiency 53
Chronic Othostatic Intolerance 53
Pots Due to Net Deficiency 53
Orhtostatic Intolerance 12
Soldiers Heart 12
Pots 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0111154
ICD10 33 I95.1
MeSH 44 D054972

Summaries for Postural Orthostatic Tachycardia Syndrome

NINDS : 54 Postural orthostatic tachycardia syndrome (POTS) is one of a group of disorders that have orthostatic intolerance (OI) as their primary symptom. OI describes a condition in which an excessively reduced volume of blood returns to the heart after an individual stands up from a lying down position. The primary symptom of OI is lightheadedness or fainting. In POTS, the lightheadedness or fainting is also accompanied by a rapid increase in heartbeat of more than 30 beats per minute, or a heart rate that exceeds 120 beats per minute, within 10 minutes of rising. The faintness or lightheadedness of POTS are relieved by lying down again. Anyone at any age can develop POTS, but the majority of individuals affected (between 75 and 80 percent) are women between the ages of 15 to 50 years of age. Some women report an increase in episodes of POTS right before their menstrual periods. POTS often begins after a pregnancy, major surgery, trauma, or a viral illness. It may make individuals unable to exercise because the activity brings on fainting spells or dizziness. Doctors aren't sure yet what causes the reduced return of blood to the heart that occurs in OI, or why the heart begins to beat so rapidly in POTS.  Current thinking is that there are a number of mechanisms.  Some individuals have peripheral denervation (neuropathic POTS); some have symptoms that are due to sustained or parosyxmal overactivity of the sympathetic nervous system (hyperadrenergic POTS); and many individuals with POTS have significant deconditioning. 

MalaCards based summary : Postural Orthostatic Tachycardia Syndrome, also known as familial orthostatic tachycardia due to norepinephrine transporter deficiency, is related to orthostatic intolerance and aortic coarctation, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Postural Orthostatic Tachycardia Syndrome is SLC44A1 (Solute Carrier Family 44 Member 1), and among its related pathways/superpathways is Hypothesized Pathways in Pathogenesis of Cardiovascular Disease. The drugs Propranolol and Bisoprolol have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are behavior/neurological and pigmentation

Disease Ontology : 12 A heart conduction disease characterized by orthostatic intolerance that has material basis in heterozygous mutation in the SLC6A2 gene on chromosome 16q12.2.

NIH Rare Diseases : 53 Postural orthostatic tachycardia syndrome (POTS) is a condition characterized by too little blood returning to the heart when moving from a lying down to a standing up position (orthostatic intolerance). Orthostatic Intolerance causes lightheadedness or fainting that can be eased by lying back down. In people with POTS, these symptoms are also accompanied by a rapid increase in heart rate. Although POTS can affect men and women of all ages, most cases are diagnosed in women between the ages of 15 and 50. The cause of POTS is unknown. However, episodes often begin after major surgery, trauma, or a viral illness. In women, episodes may also begin after pregnancy and the symptoms may worsen or the number of episodes may increase right before menstruation. The goal of treatment is to increase blood flow and improve circulatory problems that may be causing POTS.

Wikipedia : 76 Postural orthostatic tachycardia syndrome (POTS) is a condition in which a change from lying to standing... more...

Related Diseases for Postural Orthostatic Tachycardia Syndrome

Diseases related to Postural Orthostatic Tachycardia Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Related Disease Score Top Affiliating Genes
1 orthostatic intolerance 32.2 AGTR1 FBN1 SLC6A2
2 aortic coarctation 29.9 AGTR1 FBN1
3 syncope 11.7
4 chronic orthostatic intolerance 11.7
5 mitral valve prolapse 1 11.4
6 autonomic nervous system disease 11.3
7 hereditary alpha tryptasemia syndrome 11.3
8 dysautonomia 11.3
9 ehlers-danlos syndrome 10.4
10 chronic fatigue syndrome 10.4
11 mitral valve prolapse, familial, x-linked 10.4
12 hypermobility syndrome 10.3
13 panic disorder 10.3
14 multiple sclerosis 10.2
15 lyme disease 10.2
16 epilepsy 10.2
17 schizophrenia 10.2
18 brucellosis 10.2
19 heart disease 10.2
20 arachnoiditis 10.2
21 hyperthyroidism 10.2
22 hypoxia 10.2
23 neurotic disorder 10.2
24 ehlers-danlos syndrome, hypermobility type 10.1
25 storage pool platelet disease 10.1
26 anxiety 10.1
27 neuromyelitis optica 10.1
28 temporal lobe epilepsy 10.1
29 brugada syndrome 10.1
30 vitamin b12 deficiency 10.1
31 papilloma 10.1
32 complex regional pain syndrome 10.1
33 choline deficiency disease 10.1
34 hypermobile ehlers-danlos syndrome 10.1
35 neuromyelitis optica spectrum disorder 10.1
36 primary orthostatic hypotension 10.1
37 depression 10.1
38 fibromyalgia 10.1
39 pain - chronic 10.1
40 acute pandysautonomia 10.1
41 ventricular fibrillation, paroxysmal familial, 1 10.0
42 myocardial infarction 10.0
43 cardiac arrest 10.0
44 mitral valve insufficiency 10.0
45 ischemia 10.0
46 agoraphobia 10.0
47 chaotic atrial tachycardia 10.0
48 erythermalgia, primary 9.9
49 body mass index quantitative trait locus 1 9.9
50 muscle hypertrophy 9.9

Comorbidity relations with Postural Orthostatic Tachycardia Syndrome via Phenotypic Disease Network (PDN):


Anxiety Chronic Myocardial Ischemia
Dysthymic Disorder Esophagitis
Heart Disease Hypertension, Essential
Intermediate Coronary Syndrome Ischemic Heart Disease

Graphical network of the top 20 diseases related to Postural Orthostatic Tachycardia Syndrome:



Diseases related to Postural Orthostatic Tachycardia Syndrome

Symptoms & Phenotypes for Postural Orthostatic Tachycardia Syndrome

UMLS symptoms related to Postural Orthostatic Tachycardia Syndrome:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Postural Orthostatic Tachycardia Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.35 AGTR1 FBN1 GNAT1 SLC44A1 SLC6A2
2 pigmentation MP:0001186 8.8 ADAMTSL4 FBN1 GNAT1

Drugs & Therapeutics for Postural Orthostatic Tachycardia Syndrome

Drugs for Postural Orthostatic Tachycardia Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propranolol Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 525-66-6 4946
2
Bisoprolol Approved Phase 4 66722-44-9 2405
3 Antihypertensive Agents Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
4 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
5 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
6 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
8 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
9 Adrenergic beta-1 Receptor Antagonists Phase 4,Phase 2,Phase 1
10 Adrenergic Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Sympatholytics Phase 4,Phase 2,Phase 1
12 Adrenergic Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Bromides Phase 4,Phase 1,Not Applicable,Early Phase 1
14 Cholinergic Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
15 Vasodilator Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
16 Cholinesterase Inhibitors Phase 4,Phase 1,Not Applicable,Early Phase 1
17 Pyridostigmine Bromide Phase 4,Phase 1,Not Applicable,Early Phase 1 101-26-8
18
Dopamine Approved Phase 2, Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
19
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359 38101
20 Protective Agents Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable
21 Dopamine Agents Phase 2, Phase 3,Phase 1,Not Applicable
22 Antiparkinson Agents Phase 2, Phase 3,Phase 1
23 Sympathomimetics Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Cardiotonic Agents Phase 2, Phase 3,Not Applicable,Early Phase 1
25 Aromatic Amino Acid Decarboxylase Inhibitors Phase 2, Phase 3
26 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
27 Plasma Substitutes Phase 3
28
Metoprolol Approved, Investigational Phase 2 37350-58-6, 51384-51-1 4171
29
Nitric Oxide Approved Phase 1, Phase 2,Early Phase 1 10102-43-9 145068
30
Droxidopa Approved, Investigational Phase 2,Phase 1 23651-95-8 443940
31
Entacapone Approved, Investigational Phase 1, Phase 2 130929-57-6 5281081
32
Acetazolamide Approved, Vet_approved Phase 1, Phase 2 59-66-5 1986
33
AT-101 Approved, Investigational Phase 1, Phase 2 90141-22-3, 652-67-5 12597
34
Midodrine Approved Phase 1, Phase 2 133163-28-7, 42794-76-3 4195
35
Sertraline Approved Phase 1, Phase 2 79617-96-2 68617
36
Indomethacin Approved, Investigational Phase 1, Phase 2 53-86-1 3715
37
Mecamylamine Approved, Investigational Phase 1, Phase 2 60-40-2 4032
38
Clonidine Approved Phase 1, Phase 2 4205-90-7 2803
39
Isosorbide Dinitrate Approved, Investigational Phase 1, Phase 2 87-33-2 6883
40
Memantine Approved, Investigational Phase 1, Phase 2 19982-08-2 4054
41
Armodafinil Approved, Investigational Phase 1, Phase 2,Early Phase 1 112111-43-0
42
Octreotide Approved, Investigational Phase 1, Phase 2 83150-76-9 383414 6400441
43
Modafinil Approved, Investigational Phase 1, Phase 2,Early Phase 1 68693-11-8 4236
44
Iron Approved Phase 1, Phase 2 7439-89-6 23925
45
Atenolol Approved Phase 1, Phase 2 29122-68-7 2249
46
Melatonin Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 73-31-4 896
47 Vasoconstrictor Agents Phase 1, Phase 2,Not Applicable,Early Phase 1
48 Antioxidants Phase 1, Phase 2,Early Phase 1
49 Adrenergic alpha-Agonists Phase 1, Phase 2,Not Applicable,Early Phase 1
50 Cholinergic Antagonists Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS) Completed NCT02171988 Phase 4 Propranolol;Bisoprolol;Propranolol+pyridostigmine;Bisoprolol+pyridostgmine
2 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome Recruiting NCT03182725 Phase 3 Ivabradine;Placebo
3 Peripheral Dopamine in Postural Tachycardia Syndrome Active, not recruiting NCT00685919 Phase 2, Phase 3 Carbidopa;Placebo
4 A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS Not yet recruiting NCT03365414 Phase 3 Normal Saline 0.9% Infusion Solution Bag
5 The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome Unknown status NCT01761825 Phase 2 ivabradine
6 Cardiovascular Effects of Selective I(f)-Channel Blockade Unknown status NCT00865917 Phase 2 beta-blocker (Metoprolol);I(f)-blocker (ivabradine);Placebo
7 Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS) Recruiting NCT02558972 Phase 2 Northera (Droxidopa);Placebo;Northera (Droxidopa);Placebo
8 Treatment of Orthostatic Intolerance Active, not recruiting NCT00262470 Phase 1, Phase 2 Acetazolamide;Atomoxetine;Clonidine;Entacapone;Entacapone & Propranolol;Atomoxetine & Propranolol;Indomethacin;Mecamylamine;Isosorbide Dinitrate;Midodrine;Modafinil;Octreotide;Propranolol;Modafinil & Propranolol;Sertraline;memantine
9 Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS) Terminated NCT01978535 Phase 1, Phase 2 Iron infusion;Normal saline infusion
10 Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist Terminated NCT03070730 Phase 1, Phase 2 Droxidopa;Atenolol;Placebos
11 The Renin-Aldosterone Axis in Postural Tachycardia Syndrome Completed NCT00962949 Phase 1 Angiotensin II
12 Autonomic Nervous System and Chronic Fatigue Syndrome Completed NCT00580619 Phase 1 L-NMMA trimethaphan;methyldopa
13 Vagal Stimulation in POTS Recruiting NCT03124355 Phase 1 placebo sugar pill;Pyridostigmine Pill;Galantamine Pill
14 Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients Active, not recruiting NCT02854683 Phase 1 Normal Saline
15 High Sodium Diet and External Abdominal Compression in POTS Terminated NCT01771484 Phase 1
16 Palpitations and Tachycardia in Fibromyalgia Syndrome Unknown status NCT01147263
17 Cognitive Dysfunction in Postural Tachycardia Syndrome Completed NCT01366963
18 Assessment of Vascular Endothelial Function in Postural Tachycardia Syndrome Completed NCT01308099
19 Local Vasoconstriction in Postural Tachycardia Syndrome Completed NCT01210430 Early Phase 1 Losartan;Ascorbic Acid (Vitamin C);Normal Saline
20 Autonomic Profiles in Pediatric Patients With Cyclic Vomiting Syndrome (CVS), Irritable Bowel Syndrome (IBS),Postural Orthostatic Tachycardia Syndrome (POTS), Functional Abdominal Pain (FAP) or Chronic Nausea Completed NCT00728026
21 Tilt Table With Suspected Postural Orthostatic Tachycardia Syndrome (POTS) Subjects Completed NCT01617616
22 Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia Later in Life Completed NCT01367977
23 Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration Completed NCT01064739 Early Phase 1
24 EEG Characteristics in Youth POTS and/or Syncope Completed NCT02167412
25 Abdominal and Lower Extremity Compression During Tilt Table Testing in Adolescent POTS Patients Completed NCT01795469 Not Applicable
26 Qualitative Sweat Distribution During Tilt Table Procedure Completed NCT02329548 Not Applicable
27 Effect of Exercise in OI Completed NCT00770484 Not Applicable Propranolol then Placebo;Placebo then Propranolol
28 Objective Sleep Disturbances in Orthostatic Intolerance Completed NCT00581022
29 Hypnosis in Autonomic Function Completed NCT00061009
30 MRI to Assess the Effects of Dysautonomia and Chronic Nausea on Brain Transmitters Completed NCT01692561
31 PET Scan in Patients With Neurocardiologic Disorders Completed NCT00001418
32 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome Recruiting NCT03263819
33 A Study of Pyridostigmine in Postural Tachycardia Syndrome Recruiting NCT00409435 Not Applicable pyridostigmine;Placebo
34 POTS Adrenergic Ab (CIHR Aims #1&2) Recruiting NCT02673996 Phenylephrine;Isoproterenol
35 Autoimmune Basis for Postural Tachycardia Syndrome Recruiting NCT02725060 Not Applicable phenylephrine;isoproterenol
36 Hemodynamic Effects of Compression in POTS Recruiting NCT03484273 Not Applicable
37 Alterations of Attention in POTS Depending on Body Position and Hydration Recruiting NCT03253120 Not Applicable
38 Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS Recruiting NCT03261570 Early Phase 1 Pyridostigmine;Digoxin;Placebo
39 Concentration and Attentional Deficits in POTS and Other Autonomic Neuropathies Recruiting NCT03681080 Not Applicable
40 Pathophysiology of Orthostatic Intolerance Recruiting NCT00608725 Not Applicable Intrinsic Heart Rate
41 Vitamin D Deficiency and Dysautonomia Recruiting NCT03032328 Not Applicable
42 Clinical Autonomic Disorders: A Training Protocol Recruiting NCT02154009
43 External Influences Upon Ocular Homeostasis Recruiting NCT00338065 Not Applicable
44 Biospecimen Repository for Cardiac Arrhythmias at the Cleveland Clinic Recruiting NCT00921986
45 Assessment of Antibodies and Inflammatory Markers in Postural Tachycardia Syndrome Active, not recruiting NCT02196376
46 Breathing Device in Postural Orthostatic Tachycardia Syndrome (POTS) Active, not recruiting NCT00962728 Not Applicable
47 Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS) Active, not recruiting NCT01764711 Not Applicable Cosyntropin administration
48 Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening Active, not recruiting NCT01783288 Not Applicable
49 Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome Active, not recruiting NCT01563107 Not Applicable
50 Dietary Salt in Postural Tachycardia Syndrome Active, not recruiting NCT01547117 Not Applicable

Search NIH Clinical Center for Postural Orthostatic Tachycardia Syndrome

Cochrane evidence based reviews: postural orthostatic tachycardia syndrome

Genetic Tests for Postural Orthostatic Tachycardia Syndrome

Anatomical Context for Postural Orthostatic Tachycardia Syndrome

MalaCards organs/tissues related to Postural Orthostatic Tachycardia Syndrome:

41
Heart, Testes, Brain, Skin, Bone, Spinal Cord, Temporal Lobe

Publications for Postural Orthostatic Tachycardia Syndrome

Articles related to Postural Orthostatic Tachycardia Syndrome:

(show top 50) (show all 173)
# Title Authors Year
1
Demographics of a large paediatric Postural Orthostatic Tachycardia Syndrome Program. ( 29357955 )
2018
2
Activity and Exercise Intolerance After Concussion: Identification and Management of Postural Orthostatic Tachycardia Syndrome. ( 29864098 )
2018
3
Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Systematic Review. ( 29330767 )
2018
4
Periodic facial erythema in a patient with postural orthostatic tachycardia syndrome. ( 28976015 )
2018
5
The patient perspective: What postural orthostatic tachycardia syndrome patients want physicians to know. ( 29903594 )
2018
6
Youth with Chronic Pain and Postural Orthostatic Tachycardia Syndrome (POTS): Treatment Mediators of Improvement in Functional Disability. ( 29508112 )
2018
7
Autoimmunity in postural orthostatic tachycardia syndrome: Current understanding. ( 29909990 )
2018
8
From Postural Orthostatic Tachycardia Syndrome to Radiologically Isolated Syndrome. ( 29682372 )
2018
9
Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management. ( 29943373 )
2018
10
Autoimmune postural orthostatic tachycardia syndrome. ( 29687025 )
2018
11
Postural Orthostatic Tachycardia Syndrome and Its Unusual Presenting Complaints in Women: A Literature Minireview. ( 29876157 )
2018
12
Ivabradine in Postural Orthostatic Tachycardia Syndrome: Preliminary Experience in Children. ( 29027608 )
2018
13
Vagal nerve stimulation is beneficial in postural orthostatic tachycardia syndrome and epilepsy. ( 29529557 )
2018
14
Postural Orthostatic Tachycardia Syndrome during pregnancy: A systematic review of the literature. ( 29784553 )
2018
15
Postural orthostatic tachycardia syndrome and the potential role of mast cell activation. ( 30033040 )
2018
16
Utilisation of medications to reduce symptoms in children with postural orthostatic tachycardia syndrome. ( 30079848 )
2018
17
Near-infrared spectroscopy muscle oximetry of patients with postural orthostatic tachycardia syndrome. ( 30197684 )
2018
18
Therapy for fatigue and cognitive dysfunction in postural orthostatic tachycardia syndrome. ( 30198448 )
2018
19
Postural Orthostatic Tachycardia Syndrome and Vasospastic Angina: Therapeutic Approach to a Previously Unreported Association. ( 30322723 )
2018
20
Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. ( 30372565 )
2018
21
Postural orthostatic tachycardia syndrome (POTS) in teens: A guide for behavior change to manage symptoms. ( 30520065 )
2018
22
Postural Orthostatic Tachycardia Syndrome (POTS) in Denmark: Increasingly recognized or new epidemic? ( 29530592 )
2018
23
Postural orthostatic tachycardia syndrome in children and adolescents. ( 29778304 )
2018
24
Role of implantable loop recorders in patients with postural orthostatic tachycardia syndrome. ( 29989177 )
2018
25
Sleep disturbance linked to suicidal ideation in postural orthostatic tachycardia syndrome. ( 28442939 )
2017
26
Orthostatic Intolerance and Postural Orthostatic Tachycardia Syndrome in Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome, Hypermobility Type: Neurovegetative Dysregulation or Autonomic Failure? ( 28286774 )
2017
27
Comparison of Heart Rate Variability Parameters to the Autonomic Reflex Screen in Postural Orthostatic Tachycardia Syndrome and Neurogenic Orthostatic Hypotension. ( 29210841 )
2017
28
Incidence rates of Guillain BarrAc (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002-2012. ( 28720463 )
2017
29
Unexplored relationship of sleep disturbances linked to suicidal ideation and behavior in postural orthostatic tachycardia syndrome. ( 28769598 )
2017
30
Differences in neurohumoral and hemodynamic response to prolonged head-up tilt between patients with high and normal standing norepinephrine forms of postural orthostatic tachycardia syndrome. ( 28522107 )
2017
31
Human Papillomavirus Vaccine and Postural Orthostatic Tachycardia Syndrome: A Review of Current Literature. ( 28689455 )
2017
32
Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System. ( 29061232 )
2017
33
Using an exercise program to improve activity tolerance in a female with postural orthostatic tachycardia syndrome: A case report. ( 28590791 )
2017
34
Cardiovascular testing in patients with postural orthostatic tachycardia syndrome and Ehlers-Danlos syndrome type III. ( 28101744 )
2017
35
Postural orthostatic tachycardia syndrome for the otolaryngologist. ( 27578452 )
2017
36
Postural Orthostatic Tachycardia Syndrome (POTS) - A novel member of the autoimmune family. ( 26846691 )
2016
37
Postural orthostatic tachycardia syndrome is associated with platelet storage pool deficiency. ( 27631244 )
2016
38
Stimulant medication and postural orthostatic tachycardia syndrome: a tale of two cases. ( 26968177 )
2016
39
Resolution of Postural Orthostatic Tachycardia Syndrome After CT-Guided, Percutaneous T2 Ethanol Ablation for Hyperhidrosis. ( 27558116 )
2016
40
Improvement in Functioning and Psychological Distress in Adolescents With Postural Orthostatic Tachycardia Syndrome Following Interdisciplinary Treatment. ( 26983448 )
2016
41
[Clinical characteristics of orthostatic hypertension with hemodynamic response of vasovagal syncope and postural orthostatic tachycardia syndrome in children and adolescents]. ( 27055424 )
2016
42
Cardiac responses to exercise distinguish postural orthostatic tachycardia syndrome variants. ( 27884959 )
2016
43
BASCULE syndrome, orthostatic cyanosis and postural orthostatic tachycardia syndrome: time for decanting old wine? ( 27479249 )
2016
44
Recognizing postural orthostatic tachycardia syndrome. ( 26967958 )
2016
45
Cardiovascular profile in postural orthostatic tachycardia syndrome and Ehlers-Danlos syndrome type III. ( 28005189 )
2016
46
Postural orthostatic tachycardia syndrome (POTS) as presenting symptom of CIDP. ( 26879313 )
2016
47
Cooccurrence of Postural Orthostatic Tachycardia Syndrome with Two Different Clinical Entities. ( 27413567 )
2016
48
Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome. ( 27563801 )
2016
49
Human papillomavirus vaccines, complex regional pain syndrome, postural orthostatic tachycardia syndrome, and autonomic dysfunction - a review of the regulatory evidence from the European Medicines Agency. ( 27867145 )
2016
50
Use of an allostatic neurotechnology by adolescents with postural orthostatic tachycardia syndrome (POTS) is associated with improvements in heart rate variability and changes in temporal lobe electrical activity. ( 26645307 )
2016

Variations for Postural Orthostatic Tachycardia Syndrome

Expression for Postural Orthostatic Tachycardia Syndrome

Search GEO for disease gene expression data for Postural Orthostatic Tachycardia Syndrome.

Pathways for Postural Orthostatic Tachycardia Syndrome

Pathways related to Postural Orthostatic Tachycardia Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.02 AGTR1 FBN1

GO Terms for Postural Orthostatic Tachycardia Syndrome

Biological processes related to Postural Orthostatic Tachycardia Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 8.62 AGTR1 FBN1

Sources for Postural Orthostatic Tachycardia Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....